4.7 Article

Behavioral and histological neuroprotection by tamoxifen after reversible focal cerebral ischemia

Journal

EXPERIMENTAL NEUROLOGY
Volume 196, Issue 1, Pages 41-46

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.expneurol.2005.07.002

Keywords

cerebral ischemia; reversible middle cerebral artery occlusion; tamoxifen; neuroprotection; rats; long term protection; infarct size; behavior

Categories

Funding

  1. NINDS NIH HHS [NS35205] Funding Source: Medline

Ask authors/readers for more resources

We have previously shown that tamoxifen can reduce infarct sizes measured by 2,3,5,-triphenyltetrazolium chloride (TTC) staining at 72 h after 2 h of reversible middle cerebral artery occlusion (rMCAo) in rats. In this study, we tested whether improvement is found in both behavioral measures of protection and by histological measures of infarcted tissue at 7 and 14 days after 2 h rMCAo. Tamoxifen (10 mg/kg) was given once by intravenous injection 1 hr after reperfusion, i.e. 3 h after initiation of rMCAo. Neurobehavioral deficits were evaluated daily for 1 week or 2 weeks followed by infarct volumes measurements by hematoxylin-eosin (HE) staining. Tamoxifen-treated rats had significantly improved neurobehavioral deficit scores when evaluated daily throughout the 1 week or 2 week periods and showed 3 significantly reduced median infarct volumes measured after 1 week and 2 weeks. Median infarct values were 149 mm(3) (interquartile range, IQR: 92 to 258) and 124 mm(3) (IQR: 69 to 174) for the 1 and 2 week vehicle groups, respectively, compared with 5 mm(3) (IQR: 3 to 16) and 4 mm(3) (IQR: 0 to 48) for the comparable treated groups (both P < 0.05, Mann-Whitney test), giving a reduction of more than 90% in both cases. Thus, a single administration of tamoxifen given 3 h after initiation of rMCAo is extremely effective in producing long-term neuroprotection as assessed by neurobehavioral measures and histopathology in experimental stroke in rats. If these results are extrapolatable to human stroke, these data indicate that tamoxifen may be a useful neuroprotectant. (c) 2005 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available